Global Stomach Cancer and Gastric Cancer Drugs Market Research Report 2023
Stomach cancer is the fifth most common cancer in the world
According to QYResearch’s new survey, global Stomach Cancer and Gastric Cancer Drugs market is projected to reach US$ 9059.7 million in 2029, increasing from US$ 3948 million in 2022, with the CAGR of 12.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Stomach Cancer and Gastric Cancer Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Stomach Cancer and Gastric Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Stomach Cancer and Gastric Cancer Drugs market is projected to reach US$ 9059.7 million in 2029, increasing from US$ 3948 million in 2022, with the CAGR of 12.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Stomach Cancer and Gastric Cancer Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Stomach Cancer and Gastric Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Ipsen Pharma
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Eli Lilly
- Roche
- Novartis AG
- Bayer AG
- Celltrion Inc.
- TAIHO PHARMACEUTICAL CO., LTD.
- Jiangsu Hengrui Medicine Co., Ltd.
- Programmed Cell Death Protein 1 (PD-1) Inhibitors
- Human Epidermal Growth Factor Receptor (HER2) Antagonists
- Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
- Others
- Hospitals
- Clinics
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Programmed Cell Death Protein 1 (PD-1) Inhibitors
1.2.3 Human Epidermal Growth Factor Receptor (HER2) Antagonists
1.2.4 Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
1.2.5 Others
1.3 Market by Application
1.3.1 Global Stomach Cancer and Gastric Cancer Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Stomach Cancer and Gastric Cancer Drugs Market Perspective (2018-2029)
2.2 Stomach Cancer and Gastric Cancer Drugs Growth Trends by Region
2.2.1 Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Stomach Cancer and Gastric Cancer Drugs Historic Market Size by Region (2018-2023)
2.2.3 Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Region (2024-2029)
2.3 Stomach Cancer and Gastric Cancer Drugs Market Dynamics
2.3.1 Stomach Cancer and Gastric Cancer Drugs Industry Trends
2.3.2 Stomach Cancer and Gastric Cancer Drugs Market Drivers
2.3.3 Stomach Cancer and Gastric Cancer Drugs Market Challenges
2.3.4 Stomach Cancer and Gastric Cancer Drugs Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Stomach Cancer and Gastric Cancer Drugs Players by Revenue
3.1.1 Global Top Stomach Cancer and Gastric Cancer Drugs Players by Revenue (2018-2023)
3.1.2 Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Stomach Cancer and Gastric Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Stomach Cancer and Gastric Cancer Drugs Revenue
3.4 Global Stomach Cancer and Gastric Cancer Drugs Market Concentration Ratio
3.4.1 Global Stomach Cancer and Gastric Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Stomach Cancer and Gastric Cancer Drugs Revenue in 2022
3.5 Stomach Cancer and Gastric Cancer Drugs Key Players Head office and Area Served
3.6 Key Players Stomach Cancer and Gastric Cancer Drugs Product Solution and Service
3.7 Date of Enter into Stomach Cancer and Gastric Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 STOMACH CANCER AND GASTRIC CANCER DRUGS BREAKDOWN DATA BY TYPE
4.1 Global Stomach Cancer and Gastric Cancer Drugs Historic Market Size by Type (2018-2023)
4.2 Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Type (2024-2029)
5 STOMACH CANCER AND GASTRIC CANCER DRUGS BREAKDOWN DATA BY APPLICATION
5.1 Global Stomach Cancer and Gastric Cancer Drugs Historic Market Size by Application (2018-2023)
5.2 Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
6.2 North America Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
6.4 North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
7.2 Europe Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
7.4 Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
8.2 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
9.2 Latin America Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
9.4 Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
10.2 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Ipsen Pharma
11.1.1 Ipsen Pharma Company Detail
11.1.2 Ipsen Pharma Business Overview
11.1.3 Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Introduction
11.1.4 Ipsen Pharma Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.1.5 Ipsen Pharma Recent Development
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Detail
11.2.2 Merck & Co., Inc. Business Overview
11.2.3 Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Introduction
11.2.4 Merck & Co., Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.2.5 Merck & Co., Inc. Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Detail
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Stomach Cancer and Gastric Cancer Drugs Introduction
11.4.4 Eli Lilly Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.4.5 Eli Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Stomach Cancer and Gastric Cancer Drugs Introduction
11.5.4 Roche Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Detail
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Stomach Cancer and Gastric Cancer Drugs Introduction
11.6.4 Novartis AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.6.5 Novartis AG Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Stomach Cancer and Gastric Cancer Drugs Introduction
11.7.4 Bayer AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.7.5 Bayer AG Recent Development
11.8 Celltrion Inc.
11.8.1 Celltrion Inc. Company Detail
11.8.2 Celltrion Inc. Business Overview
11.8.3 Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Introduction
11.8.4 Celltrion Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.8.5 Celltrion Inc. Recent Development
11.9 TAIHO PHARMACEUTICAL CO., LTD.
11.9.1 TAIHO PHARMACEUTICAL CO., LTD. Company Detail
11.9.2 TAIHO PHARMACEUTICAL CO., LTD. Business Overview
11.9.3 TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Introduction
11.9.4 TAIHO PHARMACEUTICAL CO., LTD. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.9.5 TAIHO PHARMACEUTICAL CO., LTD. Recent Development
11.10 Jiangsu Hengrui Medicine Co., Ltd.
11.10.1 Jiangsu Hengrui Medicine Co., Ltd. Company Detail
11.10.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
11.10.3 Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Introduction
11.10.4 Jiangsu Hengrui Medicine Co., Ltd. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.10.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Programmed Cell Death Protein 1 (PD-1) Inhibitors
1.2.3 Human Epidermal Growth Factor Receptor (HER2) Antagonists
1.2.4 Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
1.2.5 Others
1.3 Market by Application
1.3.1 Global Stomach Cancer and Gastric Cancer Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Stomach Cancer and Gastric Cancer Drugs Market Perspective (2018-2029)
2.2 Stomach Cancer and Gastric Cancer Drugs Growth Trends by Region
2.2.1 Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Stomach Cancer and Gastric Cancer Drugs Historic Market Size by Region (2018-2023)
2.2.3 Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Region (2024-2029)
2.3 Stomach Cancer and Gastric Cancer Drugs Market Dynamics
2.3.1 Stomach Cancer and Gastric Cancer Drugs Industry Trends
2.3.2 Stomach Cancer and Gastric Cancer Drugs Market Drivers
2.3.3 Stomach Cancer and Gastric Cancer Drugs Market Challenges
2.3.4 Stomach Cancer and Gastric Cancer Drugs Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Stomach Cancer and Gastric Cancer Drugs Players by Revenue
3.1.1 Global Top Stomach Cancer and Gastric Cancer Drugs Players by Revenue (2018-2023)
3.1.2 Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Stomach Cancer and Gastric Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Stomach Cancer and Gastric Cancer Drugs Revenue
3.4 Global Stomach Cancer and Gastric Cancer Drugs Market Concentration Ratio
3.4.1 Global Stomach Cancer and Gastric Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Stomach Cancer and Gastric Cancer Drugs Revenue in 2022
3.5 Stomach Cancer and Gastric Cancer Drugs Key Players Head office and Area Served
3.6 Key Players Stomach Cancer and Gastric Cancer Drugs Product Solution and Service
3.7 Date of Enter into Stomach Cancer and Gastric Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 STOMACH CANCER AND GASTRIC CANCER DRUGS BREAKDOWN DATA BY TYPE
4.1 Global Stomach Cancer and Gastric Cancer Drugs Historic Market Size by Type (2018-2023)
4.2 Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Type (2024-2029)
5 STOMACH CANCER AND GASTRIC CANCER DRUGS BREAKDOWN DATA BY APPLICATION
5.1 Global Stomach Cancer and Gastric Cancer Drugs Historic Market Size by Application (2018-2023)
5.2 Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
6.2 North America Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
6.4 North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
7.2 Europe Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
7.4 Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
8.2 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
9.2 Latin America Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
9.4 Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size (2018-2029)
10.2 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Ipsen Pharma
11.1.1 Ipsen Pharma Company Detail
11.1.2 Ipsen Pharma Business Overview
11.1.3 Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Introduction
11.1.4 Ipsen Pharma Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.1.5 Ipsen Pharma Recent Development
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Detail
11.2.2 Merck & Co., Inc. Business Overview
11.2.3 Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Introduction
11.2.4 Merck & Co., Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.2.5 Merck & Co., Inc. Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Detail
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Stomach Cancer and Gastric Cancer Drugs Introduction
11.4.4 Eli Lilly Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.4.5 Eli Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Stomach Cancer and Gastric Cancer Drugs Introduction
11.5.4 Roche Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Detail
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Stomach Cancer and Gastric Cancer Drugs Introduction
11.6.4 Novartis AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.6.5 Novartis AG Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Stomach Cancer and Gastric Cancer Drugs Introduction
11.7.4 Bayer AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.7.5 Bayer AG Recent Development
11.8 Celltrion Inc.
11.8.1 Celltrion Inc. Company Detail
11.8.2 Celltrion Inc. Business Overview
11.8.3 Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Introduction
11.8.4 Celltrion Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.8.5 Celltrion Inc. Recent Development
11.9 TAIHO PHARMACEUTICAL CO., LTD.
11.9.1 TAIHO PHARMACEUTICAL CO., LTD. Company Detail
11.9.2 TAIHO PHARMACEUTICAL CO., LTD. Business Overview
11.9.3 TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Introduction
11.9.4 TAIHO PHARMACEUTICAL CO., LTD. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.9.5 TAIHO PHARMACEUTICAL CO., LTD. Recent Development
11.10 Jiangsu Hengrui Medicine Co., Ltd.
11.10.1 Jiangsu Hengrui Medicine Co., Ltd. Company Detail
11.10.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
11.10.3 Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Introduction
11.10.4 Jiangsu Hengrui Medicine Co., Ltd. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
11.10.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Programmed Cell Death Protein 1 (PD-1) Inhibitors
Table 3. Key Players of Human Epidermal Growth Factor Receptor (HER2) Antagonists
Table 4. Key Players of Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
Table 5. Key Players of Others
Table 6. Global Stomach Cancer and Gastric Cancer Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Region (2018-2023)
Table 10. Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Region (2024-2029)
Table 12. Stomach Cancer and Gastric Cancer Drugs Market Trends
Table 13. Stomach Cancer and Gastric Cancer Drugs Market Drivers
Table 14. Stomach Cancer and Gastric Cancer Drugs Market Challenges
Table 15. Stomach Cancer and Gastric Cancer Drugs Market Restraints
Table 16. Global Stomach Cancer and Gastric Cancer Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Players (2018-2023)
Table 18. Global Top Stomach Cancer and Gastric Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stomach Cancer and Gastric Cancer Drugs as of 2022)
Table 19. Ranking of Global Top Stomach Cancer and Gastric Cancer Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Stomach Cancer and Gastric Cancer Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Stomach Cancer and Gastric Cancer Drugs Product Solution and Service
Table 23. Date of Enter into Stomach Cancer and Gastric Cancer Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Type (2018-2023)
Table 27. Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Type (2024-2029)
Table 29. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Application (2018-2023)
Table 31. Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Application (2024-2029)
Table 33. North America Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 48. Ipsen Pharma Company Detail
Table 49. Ipsen Pharma Business Overview
Table 50. Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Product
Table 51. Ipsen Pharma Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 52. Ipsen Pharma Recent Development
Table 53. Merck & Co., Inc. Company Detail
Table 54. Merck & Co., Inc. Business Overview
Table 55. Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Product
Table 56. Merck & Co., Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 57. Merck & Co., Inc. Recent Development
Table 58. Bristol-Myers Squibb Company Company Detail
Table 59. Bristol-Myers Squibb Company Business Overview
Table 60. Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Product
Table 61. Bristol-Myers Squibb Company Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 62. Bristol-Myers Squibb Company Recent Development
Table 63. Eli Lilly Company Detail
Table 64. Eli Lilly Business Overview
Table 65. Eli Lilly Stomach Cancer and Gastric Cancer Drugs Product
Table 66. Eli Lilly Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 67. Eli Lilly Recent Development
Table 68. Roche Company Detail
Table 69. Roche Business Overview
Table 70. Roche Stomach Cancer and Gastric Cancer Drugs Product
Table 71. Roche Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Novartis AG Company Detail
Table 74. Novartis AG Business Overview
Table 75. Novartis AG Stomach Cancer and Gastric Cancer Drugs Product
Table 76. Novartis AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 77. Novartis AG Recent Development
Table 78. Bayer AG Company Detail
Table 79. Bayer AG Business Overview
Table 80. Bayer AG Stomach Cancer and Gastric Cancer Drugs Product
Table 81. Bayer AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 82. Bayer AG Recent Development
Table 83. Celltrion Inc. Company Detail
Table 84. Celltrion Inc. Business Overview
Table 85. Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Product
Table 86. Celltrion Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 87. Celltrion Inc. Recent Development
Table 88. TAIHO PHARMACEUTICAL CO., LTD. Company Detail
Table 89. TAIHO PHARMACEUTICAL CO., LTD. Business Overview
Table 90. TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Product
Table 91. TAIHO PHARMACEUTICAL CO., LTD. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 92. TAIHO PHARMACEUTICAL CO., LTD. Recent Development
Table 93. Jiangsu Hengrui Medicine Co., Ltd. Company Detail
Table 94. Jiangsu Hengrui Medicine Co., Ltd. Business Overview
Table 95. Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Product
Table 96. Jiangsu Hengrui Medicine Co., Ltd. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 97. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 1. Global Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Programmed Cell Death Protein 1 (PD-1) Inhibitors
Table 3. Key Players of Human Epidermal Growth Factor Receptor (HER2) Antagonists
Table 4. Key Players of Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
Table 5. Key Players of Others
Table 6. Global Stomach Cancer and Gastric Cancer Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Region (2018-2023)
Table 10. Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Region (2024-2029)
Table 12. Stomach Cancer and Gastric Cancer Drugs Market Trends
Table 13. Stomach Cancer and Gastric Cancer Drugs Market Drivers
Table 14. Stomach Cancer and Gastric Cancer Drugs Market Challenges
Table 15. Stomach Cancer and Gastric Cancer Drugs Market Restraints
Table 16. Global Stomach Cancer and Gastric Cancer Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Players (2018-2023)
Table 18. Global Top Stomach Cancer and Gastric Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stomach Cancer and Gastric Cancer Drugs as of 2022)
Table 19. Ranking of Global Top Stomach Cancer and Gastric Cancer Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Stomach Cancer and Gastric Cancer Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Stomach Cancer and Gastric Cancer Drugs Product Solution and Service
Table 23. Date of Enter into Stomach Cancer and Gastric Cancer Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Type (2018-2023)
Table 27. Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Type (2024-2029)
Table 29. Global Stomach Cancer and Gastric Cancer Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Application (2018-2023)
Table 31. Global Stomach Cancer and Gastric Cancer Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Application (2024-2029)
Table 33. North America Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 48. Ipsen Pharma Company Detail
Table 49. Ipsen Pharma Business Overview
Table 50. Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Product
Table 51. Ipsen Pharma Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 52. Ipsen Pharma Recent Development
Table 53. Merck & Co., Inc. Company Detail
Table 54. Merck & Co., Inc. Business Overview
Table 55. Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Product
Table 56. Merck & Co., Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 57. Merck & Co., Inc. Recent Development
Table 58. Bristol-Myers Squibb Company Company Detail
Table 59. Bristol-Myers Squibb Company Business Overview
Table 60. Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Product
Table 61. Bristol-Myers Squibb Company Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 62. Bristol-Myers Squibb Company Recent Development
Table 63. Eli Lilly Company Detail
Table 64. Eli Lilly Business Overview
Table 65. Eli Lilly Stomach Cancer and Gastric Cancer Drugs Product
Table 66. Eli Lilly Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 67. Eli Lilly Recent Development
Table 68. Roche Company Detail
Table 69. Roche Business Overview
Table 70. Roche Stomach Cancer and Gastric Cancer Drugs Product
Table 71. Roche Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Novartis AG Company Detail
Table 74. Novartis AG Business Overview
Table 75. Novartis AG Stomach Cancer and Gastric Cancer Drugs Product
Table 76. Novartis AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 77. Novartis AG Recent Development
Table 78. Bayer AG Company Detail
Table 79. Bayer AG Business Overview
Table 80. Bayer AG Stomach Cancer and Gastric Cancer Drugs Product
Table 81. Bayer AG Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 82. Bayer AG Recent Development
Table 83. Celltrion Inc. Company Detail
Table 84. Celltrion Inc. Business Overview
Table 85. Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Product
Table 86. Celltrion Inc. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 87. Celltrion Inc. Recent Development
Table 88. TAIHO PHARMACEUTICAL CO., LTD. Company Detail
Table 89. TAIHO PHARMACEUTICAL CO., LTD. Business Overview
Table 90. TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Product
Table 91. TAIHO PHARMACEUTICAL CO., LTD. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 92. TAIHO PHARMACEUTICAL CO., LTD. Recent Development
Table 93. Jiangsu Hengrui Medicine Co., Ltd. Company Detail
Table 94. Jiangsu Hengrui Medicine Co., Ltd. Business Overview
Table 95. Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Product
Table 96. Jiangsu Hengrui Medicine Co., Ltd. Revenue in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023) & (US$ Million)
Table 97. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Stomach Cancer and Gastric Cancer Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Type: 2022 VS 2029
Figure 3. Programmed Cell Death Protein 1 (PD-1) Inhibitors Features
Figure 4. Human Epidermal Growth Factor Receptor (HER2) Antagonists Features
Figure 5. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists Features
Figure 6. Others Features
Figure 7. Global Stomach Cancer and Gastric Cancer Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Application: 2022 VS 2029
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Stomach Cancer and Gastric Cancer Drugs Report Years Considered
Figure 12. Global Stomach Cancer and Gastric Cancer Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Stomach Cancer and Gastric Cancer Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Players in 2022
Figure 16. Global Top Stomach Cancer and Gastric Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stomach Cancer and Gastric Cancer Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Stomach Cancer and Gastric Cancer Drugs Revenue in 2022
Figure 18. North America Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 20. United States Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 24. Germany Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Share by Region (2018-2029)
Figure 32. China Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 40. Mexico Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 44. Turkey Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Ipsen Pharma Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 47. Merck & Co., Inc. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 48. Bristol-Myers Squibb Company Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 49. Eli Lilly Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 50. Roche Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 51. Novartis AG Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 52. Bayer AG Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 53. Celltrion Inc. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 54. TAIHO PHARMACEUTICAL CO., LTD. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 55. Jiangsu Hengrui Medicine Co., Ltd. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Figure 1. Global Stomach Cancer and Gastric Cancer Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Type: 2022 VS 2029
Figure 3. Programmed Cell Death Protein 1 (PD-1) Inhibitors Features
Figure 4. Human Epidermal Growth Factor Receptor (HER2) Antagonists Features
Figure 5. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists Features
Figure 6. Others Features
Figure 7. Global Stomach Cancer and Gastric Cancer Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Application: 2022 VS 2029
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Stomach Cancer and Gastric Cancer Drugs Report Years Considered
Figure 12. Global Stomach Cancer and Gastric Cancer Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Stomach Cancer and Gastric Cancer Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global Stomach Cancer and Gastric Cancer Drugs Market Share by Players in 2022
Figure 16. Global Top Stomach Cancer and Gastric Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stomach Cancer and Gastric Cancer Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Stomach Cancer and Gastric Cancer Drugs Revenue in 2022
Figure 18. North America Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 20. United States Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 24. Germany Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Share by Region (2018-2029)
Figure 32. China Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 40. Mexico Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Share by Country (2018-2029)
Figure 44. Turkey Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Stomach Cancer and Gastric Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Ipsen Pharma Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 47. Merck & Co., Inc. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 48. Bristol-Myers Squibb Company Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 49. Eli Lilly Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 50. Roche Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 51. Novartis AG Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 52. Bayer AG Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 53. Celltrion Inc. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 54. TAIHO PHARMACEUTICAL CO., LTD. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 55. Jiangsu Hengrui Medicine Co., Ltd. Revenue Growth Rate in Stomach Cancer and Gastric Cancer Drugs Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
